Clinical Trial

The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Trial Details
NCT Number NCT06707532
Lead Sponsor 4th Military Clinical Hospital with Polyclinic, Poland
Conditions Kidney Failure, Acute, Myopathy; Drugs, Heart Arrhythmia, Succinylcholine Sensitivity, Muscle Relaxation, General Anesthetic Drug Adverse Reaction, Projection
Enrollment 32 participants
Start Date 2024-08-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-27